A Phase 4 interventional study of bupropion and citalopram in Depressive Illness, sponsored by New York State Psychiatric Institute. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by New York State Psychiatric Institute · Phase 4, Interventional, and Treatment
Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.
Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.
Exclusion Criteria:
patients who did not remit with citalopram will continue at the same dose and have bupropion added
Drug: bupropion · Drug: citalopram
Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
Drug: bupropion · Drug: citalopram
FDA approved drug for treating depression
Also known as: Wellbutrin
FDA approved treatment for depression
Also known as: Celexa
Hamilton Rating Scale
Decrease in score for Hamilton Rating Scale for Depression, 17-item version
Time frame: weeks 6
This study is withdrawn, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New York State Psychiatric Institute